Rate of Progression of Transthyretin Amyloidosis

      Hereditary transthyretin (TTR) amyloidosis is an adult-onset disease characterized mainly by peripheral neuropathy and cardiomyopathy. Although disease progression is usually 5 to 15 years from time of diagnosis to death, no specific measurements of disease progression have been identified. The present study was designed to identify objective parameters to measure progression of hereditary TTR amyloidosis and determine if these parameters would show significant change within 1 year. Nine patients with biopsy-proved TTR amyloidosis and evidence of cardiac involvement were studied at baseline, 6 months, and 12 months by cardiac magnetic resonance imaging (MRI), electrocardiogram, and echocardiogram. Neurologic impairment score and electromyogram were determined at baseline and 12 months. Left ventricular mass determined by MRI and echocardiogram showed significant change at 12-month examination (p = 0.005 and p = 0.0009, respectively). Electrocardiogram and neurologic impairment score did not show significant change at 12 months. Measurement of left ventricular mass by MRI and echocardiographic techniques showed significant change in hereditary TTR cardiac amyloidosis within 1 year. In conclusion, these methods provide a means to clinically monitor progression of hereditary TTR amyloidosis and determine efficacy of therapeutic interventions.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Zeldenrust S.R.
        ATTR: diagnosis, prognosis and treatment.
        in: Gertz M.A. Rajkumar S.V. Amyloidosis: Diagnosis and Treatment. Humana Press, Springer Science, Business Media LLC, New York, NY2010: 191-204
        • Andrade C.
        A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves.
        Brain. 1952; 75: 408-427
        • Falk R.H.
        • Dubrey S.W.
        Amyloid heart disease.
        Prog Cardiovasc Dis. 2010; 52: 347-361
        • Dubrey S.W.
        • Davidoff R.
        • Skinner M.
        • Bergethon P.
        • Lewis D.
        • Falk R.H.
        Progression of ventricular wall thickening after liver transplantation for familial amyloidosis.
        Transplantation. 1997; 64: 74-80
        • Falk R.H.
        • Lee V.W.
        • Rubinow A.
        • Hood Jr, W.B.
        • Cohen A.S.
        Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis.
        Am J Cardiol. 1983; 51: 826-830
        • Park S.H.
        • Shub C.
        • Nobrega T.P.
        • Bailey K.R.
        • Seward J.B.
        Two-dimensional echocardiographic calculation of left ventricular mass as recommended by the American Society of Echocardiography: correlation with autopsy and M-mode echocardiography.
        J Am Soc Echocardiogr. 1996; 9: 119-128
        • Dyck P.J.
        • Davies J.L.
        • Litchy W.J.
        • O'Brien P.C.
        Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort.
        Neurology. 1997; 49: 230-239
        • Falk R.H.
        Diagnosis and management of the cardiac amyloidosis.
        Circulation. 2005; 112: 2047-2060
        • Coelho T.
        • Maia L.
        • Martins da Silva A.
        • Waddingtion-Cruz M.
        • Planté-Bordeneuve V.
        • Lozeron P.
        • Suhr O.B.
        • Campistol J.
        • Conceiçao I.M.
        • Schmidt H.
        • Trigo P.
        • Packman J.
        • Tafamidis Grogan D.R.
        Tafamidis (Fx-1006A): a first-in-class disease-modifying therapy for transthyretin familial amyloid.
        Amyloid. 2010; 17: 75-76
        • Block W.D.
        • Carey J.H.
        • Curtis A.C.
        • Falls H.F.
        • Jackson C.E.
        • Rukavina J.G.
        Primary systemic amyloidosis: a review and an experimental, genetic, and clinical study of 29 cases with particular emphasis on the familial form.
        Medicine (Baltimore). 1956; 35: 239-334
        • Benson M.D.
        • Dwulet F.E.
        Prealbumin and retinol binding protein serum concentrations in the Indiana type hereditary amyloidosis.
        Arthritis Rheum. 1983; 26: 1493-1498